Latest HUMIRA Stories
- Adjusted EPS Growth of 15.9 Percent (GAAP EPS Growth of 53.3 Percent) - - Confirms Double-Digit EPS Guidance Range for 2009 - - Increased 2009 Dividend by 11 Percent - ABBOTT PARK, Ill., April 15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2009. Diluted earnings per share, excluding specified items, were $0.73, reflecting 15.9 percent growth, and $0.03 above the mid-point of Abbott's previous first-quarter...
Humira Will Retain its Status as Decision Resources' Clinical Gold Standard for Crohn's Disease Through 2017, According to a New Report from Decision Resources WALTHAM, Mass., Jan.
ABBOTT PARK, Ill., Jan. 21 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec.
Percentage of Biologic-Treated Psoriasis Patients Will Double by 2017, According to a New Report from Decision Resources WALTHAM, Mass., Dec.
Increased Uptake of Current Agents and Emergence of New Therapies Will Drive Robust Annual Market Growth, According to a New Report from Decision Resources WALTHAM, Mass., Dec.
Abbott Laboratories has reported new positive data from the company's CHARM and CHOICE trials of Humira, a fully human monoclonal antibody approved for the treatment of rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohn's disease and juvenile idiopathic arthritis in the US and Europe.
Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
Abbott has announced new positive data from a sub-analysis of the company's pivotal, 52-week study, Reveal, which demonstrated that more psoriasis patients achieve efficacy when they receive continuous treatment with Humira compared to patients who interrupt their therapy.
WALTHAM, Mass., Sept. 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that 77 percent of surveyed dermatologists name Amgen/Wyeth/Takeda's Enbrel as their preferred first-line biologic therapy.
- An imitative word; an onomatopoetic word.